NEWS
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Top Lists
Shanu Modi
Memorial Sloan Kettering Cancer Center - Indore / United States
Others
AD Scientific Index ID: 4441163
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Shanu Modi's MOST POPULAR ARTICLES
1-)
Trastuzumab deruxtecan in previously treated HER2-positive breast cancerS Modi, C Saura, T Yamashita, YH Park, SB Kim, K Tamura, F Andre, ...New England Journal of Medicine 382 (7), 610-621, 20209122020
2-)
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancerS Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ...New England Journal of Medicine 387 (1), 9-20, 20227272022
3-)
The genomic landscape of endocrine-resistant advanced breast cancersP Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...Cancer cell 34 (3), 427-438. e6, 20187052018
4-)
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancerIE Krop, M Beeram, S Modi, SF Jones, SN Holden, W Yu, S Girish, ...Journal of Clinical Oncology 28 (16), 2698-2704, 20106882010
5-)
Unlocking the potential of antibody–drug conjugates for cancer therapyJZ Drago, S Modi, S ChandarlapatyNature Reviews Clinical Oncology 18 (6), 327-344, 20216762021
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept